Bröckelmann, Paul J. http://orcid.org/0000-0001-9662-9900
Müller, Horst
Gillessen, Sarah
Yang, Xiaoqin
Koeppel, Larissa
Pilz, Veronika
Marinello, Patricia
Kaskel, Peter
Raut, Monika
Fuchs, Michael
Borchmann, Peter
Engert, Andreas
von Tresckow, Bastian http://orcid.org/0000-0003-1410-4487
Article History
Received: 29 May 2021
Revised: 22 September 2021
Accepted: 27 September 2021
First Online: 9 October 2021
Competing interests
: PJB declares research funding by BeiGene, Bristol Myers Squibb, MSD Sharp & Dohme and Takeda, honoraria by Bristol Myers Squibb and Takeda and nonfinancial support by Celgene. XY, PM and MR are employed by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and have ownership interests with MERCK & CO., INC., Kenilworth, NJ, USA. LK and VP are employed at MSD Sharp & Dohme GmbH, Haar, Germany. PK is employed at MSD Sharp & Dohme GmbH, Haar, Germany and has ownership interests with MERCK & CO., INC., Kenilworth, NJ, USA. BvT reports nonfinancial support from AbbVie, personal fees and nonfinancial support from BMS; personal fees from Amgen, AstraZeneca, Pfizer, Gilead Sciences, Pentixafarm, and Roche; grants, personal fees, and nonfinancial support from MSD and Takeda; and grants, personal fees and nonfinancial support from Novartis. All other authors do not declare potential conflicts of interest.